LOS ANGELES–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24XENT&src=ctag” target=”_blank”gt;$XENTlt;/agt; lt;a href=”https://twitter.com/hashtag/CLASSACTION?src=hash” target=”_blank”gt;#CLASSACTIONlt;/agt;–Glancy
Prongay & Murray LLP (“GPM”) announces an investigation on
behalf of Intersect ENT, Inc. (“Intersect ENT” or the “Company”)
(NASDAQ: XENT)
investors concerning the Company and its officers’ possible violations
of federal securities laws.
If you are a shareholder who suffered a loss, click here to
participate.
If you wish to learn more about this action, or if you have any
questions concerning this announcement or your rights or interests with
respect to these matters, please contact Lesley Portnoy, Esquire, at
310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected],
or visit our website at www.glancylaw.com.
On May 6, 2019, the Company disclosed a first quarter loss of $10.8
million, as well as a lowered guidance for the remainder of 2019. In
addition to this news, the Company also reported that its CEO of 11
years will be stepping down on June 5th.
On this news, the Company’s share price fell sharply during intraday
trading, thereby injuring investors.
If you purchased Intersect ENT securities, have information or would
like to learn more about these claims, or have any questions concerning
this announcement or your rights or interests with respect to these
matters, please contact Lesley F. Portnoy, Esquire, of GPM, 1925 Century
Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150,
Toll-Free at 888-773-9224, by email to [email protected],
or visit our website at www.glancylaw.com.
If you inquire by email please include your mailing address, telephone
number and number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
Contacts
Glancy Prongay & Murray LLP, Los Angeles/New York
Lesley F.
Portnoy, 310-201-9150 or 888-773-9224
[email protected]
www.glancylaw.com
